Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: Yahoo! Finance
precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22. “We look forward to sharing additional preclinical data from our potent and selective first-in-class KAT6A degrader development candidate, PRT13722. We believe that our selective KAT6A degrader, with the potential for improved efficacy and tolerability in combination with other standard of care agents, has the potential to be a promising new therapy for patients with ER+ breast cancer. We expect to file an IND in the middle of this year and enter clinical trials in the second half of 2026,” stated Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude. Details on the poster presentation are as follows: Poster Details: Title: First-in-class potent and selective oral KAT6A degrader development candida
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual MeetingGlobeNewswire
- Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.MarketBeat
- Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]Yahoo! Finance
- Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026GlobeNewswire
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]Yahoo! Finance
PRLD
Earnings
- 3/10/26 - Miss
PRLD
Sec Filings
- 3/19/26 - Form 3
- 3/12/26 - Form 8-K
- 3/12/26 - Form 424B5
- PRLD's page on the SEC website